A carregar...
BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). Although randomized evidence demonstrates that imatinib (a commercially available TKI) prolongs event–free survival in patients with CML, some patients develop imatinib intolerance or resistance. I...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3001986/ https://ncbi.nlm.nih.gov/pubmed/21188137 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/currents.RRN1204 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|